Abu Huraira Bin Gulzar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Abu Huraira Bin Gulzar has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Asad Ali Ahmed Cheema
Department of Medicine, International School of Medicine, International University of Kyrgyzstan, Bishkek, Kyrgyzstan
3 shared publications Hafiza Qurat Ul Ain
Department of Medicine, CMH Multan, Punjab, Pakistan
3 shared publicationsDanaish Kumar
Department of Medicine, Karachi Medical and Dental College, Karachi, Pakistan
2 shared publicationsInshal Jawed
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
2 shared publications- Mirza Ammar Arshad
Department of Medicine Rahbar Medical & Dental College Lahore Pakistan
2 shared publications Mohammad Tufail
Sindh Government Hospital Karachi , Karachi 74000, Sindh
2 shared publications
Latest Publications
- 4 November 2026
- Published by Elsevier in Heart & Lung
- Vol. 81
Efficacy and safety of add-on sotatercept therapy for pulmonary arterial hypertension. A systematic review and meta-analysis
- 4 November 2026
- Published by Elsevier in Heart & Lung
- Vol. 81
Efficacy and safety of add-on sotatercept therapy for pulmonary arterial hypertension. A systematic review and meta-analysis
- Open Access
- 22 October 2026
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (6)
National Trends and Predictors of Adverse Outcomes in Hypoglycemia Hospitalizations in the United States, 2017–2022
Objective: To assess national trends and inpatient outcomes among adults hospitalized with a primary diagnosis of hypoglycemia in the United States from 2017 to 2022. Methods: We conducted a retrospective cross‐sectional analysis of the National Inpatient Sample. Adult hospitalizations aged 18 years or older with a principal ICD‐10‐CM diagnosis of hypoglycemia were included. The annual share of primary hypoglycemia hospitalizations was calculated per 100,000 adult NIS discharges. Outcomes included in‐hospital mortality, length of stay(LOS), and inflation‐adjusted hospital cost standardized to 2022 US dollars. Multivariable survey‐weighted logistic regression was used for mortality, a survey‐weighted generalized linear model (GLM) with a quasi‐Poisson distribution and log link was used for LOS, and a survey‐weighted GLM with a gamma distribution and log link was used for inflation‐adjusted hospital cost. Results: The analysis included 330,910 weighted hypoglycemia hospitalizations. Mean age was 67 years; 52% were women; and 70% were Medicare‐insured. Diabetes mellitus (91%) was the most common comorbidity, while obesity (17%) was least common. Primary‐hypoglycemia discharges peaked in 2019 (195 per 100,000 adult NIS discharges), declined in 2021 (180), and increased again in 2022 (190). Mortality occurred in 1.6%, and median LOS was 3 days. Compared with 2017, adjusted mortality odds were higher in 2020 (OR 1.30, 95% CI 1.04–1.61), 2021 (OR 1.44, 95% CI 1.16–1.79), and 2022 (OR 1.33, 95% CI 1.07–1.65). Similarly, LOS and hospital costs were also higher in 2020, 2021, and 2022 compared to 2017. Congestive heart failure (CHF) and AF were associated with higher mortality odds, LOS, and cost. Conclusion: Primary hypoglycemia hospitalizations declined during the pandemic years but became more severe and resource‐intensive over time. Patients with CHF or AF had higher mortality, higher LOS, and higher hospital costs, highlighting the need for integrated hypoglycemia surveillance and cardiometabolic care.
- 22 October 2026
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (6)
Open AccessNational Trends and Predictors of Adverse Outcomes in Hypoglycemia Hospitalizations in the United States, 2017–2022
Objective: To assess national trends and inpatient outcomes among adults hospitalized with a primary diagnosis of hypoglycemia in the United States from 2017 to 2022. Methods: We conducted a retrospective cross‐sectional analysis of the National Inpatient Sample. Adult hospitalizations aged 18 years or older with a principal ICD‐10‐CM diagnosis of hypoglycemia were included. The annual share of primary hypoglycemia hospitalizations was calculated per 100,000 adult NIS discharges. Outcomes included in‐hospital mortality, length of stay(LOS), and inflation‐adjusted hospital cost standardized to 2022 US dollars. Multivariable survey‐weighted logistic regression was used for mortality, a survey‐weighted generalized linear model (GLM) with a quasi‐Poisson distribution and log link was used for LOS, and a survey‐weighted GLM with a gamma distribution and log link was used for inflation‐adjusted hospital cost. Results: The analysis included 330,910 weighted hypoglycemia hospitalizations. Mean age was 67 years; 52% were women; and 70% were Medicare‐insured. Diabetes mellitus (91%) was the most common comorbidity, while obesity (17%) was least common. Primary‐hypoglycemia discharges peaked in 2019 (195 per 100,000 adult NIS discharges), declined in 2021 (180), and increased again in 2022 (190). Mortality occurred in 1.6%, and median LOS was 3 days. Compared with 2017, adjusted mortality odds were higher in 2020 (OR 1.30, 95% CI 1.04–1.61), 2021 (OR 1.44, 95% CI 1.16–1.79), and 2022 (OR 1.33, 95% CI 1.07–1.65). Similarly, LOS and hospital costs were also higher in 2020, 2021, and 2022 compared to 2017. Congestive heart failure (CHF) and AF were associated with higher mortality odds, LOS, and cost. Conclusion: Primary hypoglycemia hospitalizations declined during the pandemic years but became more severe and resource‐intensive over time. Patients with CHF or AF had higher mortality, higher LOS, and higher hospital costs, highlighting the need for integrated hypoglycemia surveillance and cardiometabolic care.
- Open Access
- 20 August 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (4) , e70446
Clinical Outcomes of Pulsed Field Vs. Thermal Ablation for Paroxysmal Atrial Fibrillation: Systematic Review and Meta‐Analysis of Randomized Evidence
Aims: Pulsed field ablation (PFA) is a non‐thermal alternative to conventional thermal ablation for paroxysmal atrial fibrillation (AF). We conducted an updated systematic review and meta‐analysis of randomized evidence comparing efficacy, safety, and procedural outcomes. Methods: PubMed/MEDLINE and the Cochrane Central Register of Controlled Trials were searched from inception through March 2026 for randomized controlled trials (RCTs) comparing PFA with thermal ablation in adults undergoing first catheter ablation for paroxysmal AF. Risk ratios (RRs) or mean differences (MDs) with 95% confidence intervals (CIs) were pooled using random‐effects models. Results: Four RCTs enrolling 1 393 patients were included. PFA showed no statistically detectable difference in 12‐month treatment success (RR, 1.04; 95% CI, 0.97 to 1.12; I 2 = 7%), recurrent atrial arrhythmias (RR, 1.00; 95% CI, 0.77 to 1.29; I 2 = 42%), or composite serious adverse events (RR, 0.71; 95% CI, 0.32 to 1.57; I 2 = 7%). PFA shortened procedure time (MD, −22.42 min; 95% CI, −33.44 to −11.39; I 2 = 91%) and LA dwell time (MD, −25.73 min; 95% CI, −34.66 to −16.79; I 2 = 92%), but increased fluoroscopy time (MD, 7.34 min; 95% CI, 0.39 to 14.30; I 2 = 98%). Conclusions: Across the included trial configurations, 12‐month efficacy estimates did not differ detectably. Sparse safety events and wide confidence intervals precluded equivalence claims. Pooled procedure and LA dwell times favored PFA, but platform, comparator, and workflow heterogeneity limit generalizability. Procedural findings are exploratory and should not be interpreted as direct energy‐specific effects.
- 20 August 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (4) , e70446
Open AccessClinical Outcomes of Pulsed Field Vs. Thermal Ablation for Paroxysmal Atrial Fibrillation: Systematic Review and Meta‐Analysis of Randomized Evidence
Aims: Pulsed field ablation (PFA) is a non‐thermal alternative to conventional thermal ablation for paroxysmal atrial fibrillation (AF). We conducted an updated systematic review and meta‐analysis of randomized evidence comparing efficacy, safety, and procedural outcomes. Methods: PubMed/MEDLINE and the Cochrane Central Register of Controlled Trials were searched from inception through March 2026 for randomized controlled trials (RCTs) comparing PFA with thermal ablation in adults undergoing first catheter ablation for paroxysmal AF. Risk ratios (RRs) or mean differences (MDs) with 95% confidence intervals (CIs) were pooled using random‐effects models. Results: Four RCTs enrolling 1 393 patients were included. PFA showed no statistically detectable difference in 12‐month treatment success (RR, 1.04; 95% CI, 0.97 to 1.12; I 2 = 7%), recurrent atrial arrhythmias (RR, 1.00; 95% CI, 0.77 to 1.29; I 2 = 42%), or composite serious adverse events (RR, 0.71; 95% CI, 0.32 to 1.57; I 2 = 7%). PFA shortened procedure time (MD, −22.42 min; 95% CI, −33.44 to −11.39; I 2 = 91%) and LA dwell time (MD, −25.73 min; 95% CI, −34.66 to −16.79; I 2 = 92%), but increased fluoroscopy time (MD, 7.34 min; 95% CI, 0.39 to 14.30; I 2 = 98%). Conclusions: Across the included trial configurations, 12‐month efficacy estimates did not differ detectably. Sparse safety events and wide confidence intervals precluded equivalence claims. Pooled procedure and LA dwell times favored PFA, but platform, comparator, and workflow heterogeneity limit generalizability. Procedural findings are exploratory and should not be interpreted as direct energy‐specific effects.
- 6 July 2026
- Published by SAGE Publications in Journal of Integrative and Complementary Medicine
Music Intervention for Anxiety and Pain During Breast Biopsy Procedures: A Comprehensive Systematic Review and Meta-Analysis of Randomized Controlled Trials
Introduction: Breast biopsies often cause anxiety and pain that influence patients’ experience and procedure outcomes. Music interventions offer a practical alternative to pharmacological methods for reducing these effects. Methods: We conducted a PRISMA-compliant systematic review and meta-analysis to evaluate the efficacy of music during breast biopsies. We searched PubMed, Cochrane CENTRAL Library, EMBASE, and ClinicalTrials.gov up to May 2025. We included randomized controlled trials (RCTs) comparing music interventions with routine care without music intervention. The primary outcomes were anxiety and pain scores; secondary outcomes assessed changes in these scores before and after the procedure. We calculated standardized mean differences (SMDs) with 95% confidence intervals (CIs) using a random-effects model. Results: Seven RCTs with 606 participants met the inclusion criteria. The mean age of participants was 50.8 years. Anxiety scores were significantly lower in the music group compared with controls (SMD = –0.22, 95% CI: –0.38 to –0.06, p < 0.05, I 2 = 0%). Anxiety reduction from pre- to postprocedure was also greater with music (SMD = 0.25, 95% CI: 0.07–0.44, p < 0.05, I 2 = 0%). However, pain scores did not differ significantly (SMD = –0.33, 95% CI: –0.83 to 0.17, p > 0.05, I 2 = 82%). Conclusion: Music interventions were associated with a small but statistically significant reduction in anxiety during breast biopsy procedures, but no significant reduction in pain. These findings support music as a safe, nonpharmacological option to improve patient experience, particularly with respect to procedural anxiety.
- 6 July 2026
- Published by SAGE Publications in Journal of Integrative and Complementary Medicine
Music Intervention for Anxiety and Pain During Breast Biopsy Procedures: A Comprehensive Systematic Review and Meta-Analysis of Randomized Controlled Trials
Introduction: Breast biopsies often cause anxiety and pain that influence patients’ experience and procedure outcomes. Music interventions offer a practical alternative to pharmacological methods for reducing these effects. Methods: We conducted a PRISMA-compliant systematic review and meta-analysis to evaluate the efficacy of music during breast biopsies. We searched PubMed, Cochrane CENTRAL Library, EMBASE, and ClinicalTrials.gov up to May 2025. We included randomized controlled trials (RCTs) comparing music interventions with routine care without music intervention. The primary outcomes were anxiety and pain scores; secondary outcomes assessed changes in these scores before and after the procedure. We calculated standardized mean differences (SMDs) with 95% confidence intervals (CIs) using a random-effects model. Results: Seven RCTs with 606 participants met the inclusion criteria. The mean age of participants was 50.8 years. Anxiety scores were significantly lower in the music group compared with controls (SMD = –0.22, 95% CI: –0.38 to –0.06, p < 0.05, I 2 = 0%). Anxiety reduction from pre- to postprocedure was also greater with music (SMD = 0.25, 95% CI: 0.07–0.44, p < 0.05, I 2 = 0%). However, pain scores did not differ significantly (SMD = –0.33, 95% CI: –0.83 to 0.17, p > 0.05, I 2 = 82%). Conclusion: Music interventions were associated with a small but statistically significant reduction in anxiety during breast biopsy procedures, but no significant reduction in pain. These findings support music as a safe, nonpharmacological option to improve patient experience, particularly with respect to procedural anxiety.
- Open Access
- 23 June 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (6) , e70392
Trends and Disparities in Acute Myocardial Infarction‐Related Mortality With Co‐Listed Nicotine Dependence in the United States, 1999–2020
Background: Nicotine use is a major modifiable risk factor for acute myocardial infarction (AMI), yet national mortality patterns involving co‐listed nicotine dependence remain under‐characterized. Methods: Using CDC WONDER Multiple Cause of Death data from 1999 to 2020, we evaluated AMI‐related mortality among US adults aged ≥ 25 years with co‐listed death‐certificate‐coded nicotine dependence, operationally defined using ICD‐10 F17.0–F17.9. AMI was identified using ICD‐10 I21.0–I22.9. Age‐adjusted mortality rates (AAMRs) per 100 000 population were calculated using the 2000 US standard population. Temporal trends were assessed using Joinpoint regression and stratified by sex, age, race/ethnicity, region, urbanization, state, and place of death. Results: From 1999 to 2020, 357 167 AMI‐related deaths with co‐listed nicotine dependence occurred among adults aged ≥ 25 years. The AAMR increased from 1.64 to 9.46 per 100 000 population (average annual percent change, 10.27%; p < 0.001). Men had higher AAMRs than women (11.30 vs. 4.27), with significant increases in both groups. Mortality increased with age, highest among adults aged ≥ 85 years (33.55) and lowest among those aged 35–44 years (0.83). Non‐Hispanic American Indian/Alaska Native adults had the highest AAMR (10.30). Rates were higher in the Midwest and South, nonmetropolitan areas exceeded metropolitan areas, and the highest state‐level AAMRs occurred in North Dakota and Wyoming. Most deaths occurred in inpatient facilities or at home. Conclusion: AMI‐related mortality with co‐listed nicotine dependence increased substantially from 1999 to 2020, with persistent demographic and geographic disparities. These findings may inform targeted tobacco‐control, nicotine‐cessation, and cardiovascular prevention strategies for high‐risk populations over time.
- 23 June 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (6) , e70392
Open AccessTrends and Disparities in Acute Myocardial Infarction‐Related Mortality With Co‐Listed Nicotine Dependence in the United States, 1999–2020
Background: Nicotine use is a major modifiable risk factor for acute myocardial infarction (AMI), yet national mortality patterns involving co‐listed nicotine dependence remain under‐characterized. Methods: Using CDC WONDER Multiple Cause of Death data from 1999 to 2020, we evaluated AMI‐related mortality among US adults aged ≥ 25 years with co‐listed death‐certificate‐coded nicotine dependence, operationally defined using ICD‐10 F17.0–F17.9. AMI was identified using ICD‐10 I21.0–I22.9. Age‐adjusted mortality rates (AAMRs) per 100 000 population were calculated using the 2000 US standard population. Temporal trends were assessed using Joinpoint regression and stratified by sex, age, race/ethnicity, region, urbanization, state, and place of death. Results: From 1999 to 2020, 357 167 AMI‐related deaths with co‐listed nicotine dependence occurred among adults aged ≥ 25 years. The AAMR increased from 1.64 to 9.46 per 100 000 population (average annual percent change, 10.27%; p < 0.001). Men had higher AAMRs than women (11.30 vs. 4.27), with significant increases in both groups. Mortality increased with age, highest among adults aged ≥ 85 years (33.55) and lowest among those aged 35–44 years (0.83). Non‐Hispanic American Indian/Alaska Native adults had the highest AAMR (10.30). Rates were higher in the Midwest and South, nonmetropolitan areas exceeded metropolitan areas, and the highest state‐level AAMRs occurred in North Dakota and Wyoming. Most deaths occurred in inpatient facilities or at home. Conclusion: AMI‐related mortality with co‐listed nicotine dependence increased substantially from 1999 to 2020, with persistent demographic and geographic disparities. These findings may inform targeted tobacco‐control, nicotine‐cessation, and cardiovascular prevention strategies for high‐risk populations over time.
- 16 March 2026
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 55 (3)
Efficacy of HMB supplementation as an adjunct to resistance training in older adults: a comprehensive meta-analysis
Background: Resistance training has robust evidence for improving muscle health in older adults; however, the additional benefit of adjunctive supplementation with β-hydroxy β-methylbutyrate (HMB) remains unclear. This systematic review and meta-analysis evaluated the effect of HMB supplementation combined with resistance training on body composition and muscle strength in adults aged 50 years and older. Methods: Four databases (PubMed, Scopus, Clinicaltrials.gov, and Cochrane) were systematically searched for randomized controlled trials investigating HMB supplementation with resistance training in older adults. The main results examined fat mass, muscle mass, and muscle strength. Meta-analyses were conducted using robust variance estimation with small-sample corrections. The Cochrane RoB 2.0 tool was used to assess the risk of bias. Results: A total of 561 participants were involved in 13 RCTs. According to meta-analysis data, supplementing with HMB is not advantageous concerning fat mass (SMD = 0.24, 95% CI: −0.01 to 0.49), muscle mass (SMD = 0.05, 95% CI: −0.10 to 0.20), and muscle strength (SMD = 0.04, 95% CI: −0.72 to 0.63). There was low heterogeneity for body composition outcomes but high heterogeneity for strength measures. No evidence of publication bias was detected. Conclusions: The combination of HMB supplementation and resistance training does not improve body composition or muscle strength in adults aged 50 years and older. Based on the available evidence, HMB supplementation cannot be recommended as a routine adjunct to resistance training in individuals who are able to undertake structured exercise.
- 16 March 2026
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 55 (3)
Efficacy of HMB supplementation as an adjunct to resistance training in older adults: a comprehensive meta-analysis
Background: Resistance training has robust evidence for improving muscle health in older adults; however, the additional benefit of adjunctive supplementation with β-hydroxy β-methylbutyrate (HMB) remains unclear. This systematic review and meta-analysis evaluated the effect of HMB supplementation combined with resistance training on body composition and muscle strength in adults aged 50 years and older. Methods: Four databases (PubMed, Scopus, Clinicaltrials.gov, and Cochrane) were systematically searched for randomized controlled trials investigating HMB supplementation with resistance training in older adults. The main results examined fat mass, muscle mass, and muscle strength. Meta-analyses were conducted using robust variance estimation with small-sample corrections. The Cochrane RoB 2.0 tool was used to assess the risk of bias. Results: A total of 561 participants were involved in 13 RCTs. According to meta-analysis data, supplementing with HMB is not advantageous concerning fat mass (SMD = 0.24, 95% CI: −0.01 to 0.49), muscle mass (SMD = 0.05, 95% CI: −0.10 to 0.20), and muscle strength (SMD = 0.04, 95% CI: −0.72 to 0.63). There was low heterogeneity for body composition outcomes but high heterogeneity for strength measures. No evidence of publication bias was detected. Conclusions: The combination of HMB supplementation and resistance training does not improve body composition or muscle strength in adults aged 50 years and older. Based on the available evidence, HMB supplementation cannot be recommended as a routine adjunct to resistance training in individuals who are able to undertake structured exercise.
- 30 October 2025
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
- Vol. 105 (5) , 404-411
Synergistic Effects of Vitamin D Supplementation and Resistance Training on Insulin-Like Growth Factor 1 and Muscle Health
Background: The interaction between vitamin D and insulin-like growth factor 1 in resistance-power training is not fully elucidated, despite their established roles in muscle physiology. Research compiles data about how resistance training and vitamin D supplementation affect the results of muscle parameters alongside serum insulin-like growth factor 1 concentrations. Methods: The research analysis utilized PRISMA guidelines. Seventeen studies were reviewed, including 11 randomized controlled trials and six observational studies. The included studies examined children, adults, the elderly, and patients with metabolic or hormonal disorders. The primary outcomes were serum insulin-like growth factor 1 and insulin-like growth factor–binding proteins, as well as muscle strength and physical function. Results: Seventeen studies were included in the systematic review. Voluntary muscle expression of insulin-like growth factor 1 increased by at least 20%–30% in elderly women through resistance training ( P < 0.01) though combined training increased muscle insulin-like growth factor 1 levels and functional capacity by 22% ( P = 0.01). Data confirm a positive association between serum 25(OH)D and insulin-like growth factor 1 levels, while limited evidence suggests a moderate reduction in insulin-like growth factor–binding proteins. Conclusions: The combination and individual effects of vitamin D supplementation with resistance training systems enhance insulin-like growth factor 1 bioavailability and muscle health in vitamin D–deficient adults.
- 30 October 2025
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
- Vol. 105 (5) , 404-411
Synergistic Effects of Vitamin D Supplementation and Resistance Training on Insulin-Like Growth Factor 1 and Muscle Health
Background: The interaction between vitamin D and insulin-like growth factor 1 in resistance-power training is not fully elucidated, despite their established roles in muscle physiology. Research compiles data about how resistance training and vitamin D supplementation affect the results of muscle parameters alongside serum insulin-like growth factor 1 concentrations. Methods: The research analysis utilized PRISMA guidelines. Seventeen studies were reviewed, including 11 randomized controlled trials and six observational studies. The included studies examined children, adults, the elderly, and patients with metabolic or hormonal disorders. The primary outcomes were serum insulin-like growth factor 1 and insulin-like growth factor–binding proteins, as well as muscle strength and physical function. Results: Seventeen studies were included in the systematic review. Voluntary muscle expression of insulin-like growth factor 1 increased by at least 20%–30% in elderly women through resistance training ( P < 0.01) though combined training increased muscle insulin-like growth factor 1 levels and functional capacity by 22% ( P = 0.01). Data confirm a positive association between serum 25(OH)D and insulin-like growth factor 1 levels, while limited evidence suggests a moderate reduction in insulin-like growth factor–binding proteins. Conclusions: The combination and individual effects of vitamin D supplementation with resistance training systems enhance insulin-like growth factor 1 bioavailability and muscle health in vitamin D–deficient adults.